Financial Snapshot

Revenue
$897.6M
TTM
Gross Margin
50.6%
TTM
Net Earnings
-$146.4M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
73.9%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$1.218B
Q3 2024
Cash
Q3 2024
P/E
-14.83
Nov 29, 2024 EST
Free Cash Flow
$33.27M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $938.5M $879.4M $737.9M $228.5M $65.97M $31.10M
YoY Change 6.71% 19.19% 222.87% 246.43% 112.15%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $938.5M $879.4M $737.9M $228.5M $65.97M $31.10M
Cost Of Revenue $463.2M $456.4M $403.3M $92.96M $29.93M $18.38M
Gross Profit $475.2M $423.1M $334.6M $135.6M $36.04M $12.72M
Gross Profit Margin 50.64% 48.11% 45.34% 59.32% 54.63% 40.89%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $331.9M $356.6M $188.2M $40.99M $36.85M $9.602M
YoY Change -6.91% 89.48% 359.15% 11.22% 283.76%
% of Gross Profit 69.85% 84.28% 56.25% 30.23% 102.24% 75.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $141.1M $141.4M $96.24M $7.866M $7.393M $2.569M
YoY Change -0.18% 46.9% 1123.54% 6.4% 187.83%
% of Gross Profit 29.7% 33.42% 28.77% 5.8% 20.51% 20.2%
Operating Expenses $390.1M $585.8M $230.0M $43.26M $39.14M $38.63M
YoY Change -33.4% 154.71% 431.55% 10.54% 1.31%
Operating Profit $84.78M -$161.1M $104.6M $92.31M -$3.097M -$25.92M
YoY Change -152.62% -254.05% 13.32% -3080.5% -88.05%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense -$59.79M -$49.43M -$21.19M -$4.397M -$491.0K -$2.815M
YoY Change 20.96% 133.33% 381.81% 795.52% -82.56%
% of Operating Profit -70.52% -20.25% -4.76%
Other Income/Expense, Net -$56.99M -$2.272M $9.632M -$3.613M -$270.0K $0.00
YoY Change 2408.19% -123.59% -366.59% 1238.15%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income $27.80M -$163.4M $91.96M $82.45M -$8.491M $5.481M
YoY Change -117.01% -277.69% 11.53% -1071.05% -254.92%
Income Tax $145.1M $105.5M $104.1M $42.30M $10.33M $1.772M
% Of Pretax Income 522.15% 113.23% 51.3% 32.33%
Net Earnings -$117.3M -$269.2M -$14.68M $38.40M -$18.27M -$562.0K
YoY Change -56.4% 1734.04% -138.22% -310.15% 3151.54%
Net Earnings / Revenue -12.5% -30.61% -1.99% 16.8% -27.7% -1.81%
Basic Earnings Per Share -$0.34 -$0.81 -$0.20 $0.15
Diluted Earnings Per Share -$0.34 -$0.81 -$50.53K $141.8K -$69.90K -$4.472K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $84.85M $99.12M $16.40M $6.418M $73.09M
YoY Change -14.39% 504.3% 155.57% -91.22%
Cash & Equivalents $84.85M $99.12M $16.40M
Short-Term Investments
Other Short-Term Assets $52.31M $19.53M $6.169M $2.693M $1.019M
YoY Change 167.88% 216.55% 129.11% 164.15%
Inventory $164.5M $137.6M $37.35M $30.69M $15.96M
Prepaid Expenses
Receivables $16.58M $17.41M $7.270M $5.056M $2.765M
Other Receivables $0.00 $285.0K $4.053M $5.337M $1.035M
Total Short-Term Assets $318.3M $274.0M $71.25M $50.19M $93.87M
YoY Change 16.17% 284.54% 41.96% -46.53%
Property, Plant & Equipment $608.2M $513.6M $156.0M $104.2M $40.75M
YoY Change 18.42% 229.29% 49.62% 155.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.977M $7.628M $11.55M $10.93M $2.039M
YoY Change -8.53% -33.94% 5.67% 436.05%
Other Assets $12.77M $2.499M $2.442M $3.808M $2.057M
YoY Change 410.84% 2.33% -35.87% 85.13%
Total Long-Term Assets $2.078B $2.272B $258.4M $143.9M $59.53M
YoY Change -8.54% 779.15% 79.54% 141.76%
Total Assets $2.396B $2.546B $329.7M $194.1M $153.4M
YoY Change
Accounts Payable $40.50M $45.17M $18.29M $18.54M $7.809M
YoY Change -10.34% 146.94% -1.35% 137.46%
Accrued Expenses $50.65M $48.71M $15.69M $3.112M $1.776M
YoY Change 3.98% 210.49% 404.21% 75.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $24.46M $13.77M $7.814M $9.807M $4.262M
YoY Change 77.65% 76.23% -20.32% 130.12%
Total Short-Term Liabilities $386.6M $469.9M $116.3M $56.34M $23.55M
YoY Change -17.71% 304.04% 106.4% 139.26%
Long-Term Debt $388.5M $276.2M $32.48M $15.82M $2.854M
YoY Change 40.7% 750.23% 105.36% 454.2%
Other Long-Term Liabilities $82.85M $58.00M $12.66M $0.00 $247.6K
YoY Change 42.85% 358.1% -100.0%
Total Long-Term Liabilities $471.4M $334.1M $45.14M $15.82M $3.101M
YoY Change 41.07% 640.25% 185.41% 409.95%
Total Liabilities $1.055B $1.070B $182.5M $82.36M $30.02M
YoY Change -1.44% 486.3% 121.57% 174.38%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 342.8M shares 331.4M shares 290.4M shares 263.9M shares
Diluted Shares Outstanding 342.8M shares 331.4M shares 290.4M shares 270.7M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.1701 Billion

About Verano Holdings Corp.

Verano Holdings Corp. engages in the business of of licensed cannabis cultivation, processing, wholesale distribution and retail facilities. The company is headquartered in Chicago, Illinois. The company went IPO on 2021-02-17. The firm is focused on the development of communal wellness by providing responsible access to regulated medical and adult-use cannabis products to customers. The firm produces a variety of cannabis products sold under its portfolio of consumer brands, including Verano, MUV, Savvy, BITS, Encore and Avexia. The company operates businesses in 13 states, including 138 retail dispensaries and 14 production facilities with over 1,000,000 square feet of cultivation capacity. The company also designs, builds and operates branded retail environments, including Zen Leaf and MUV dispensaries that deliver a cannabis shopping experience in both medical and adult-use markets. Its Verano product line offers a curated collection of cannabis strains, pre-rolls, vapes, and extracts, including Tire Fire Swift Lifts, Grape Bubble Gum Flower, and Sunshine OG Live Resin Cart.

Industry: Agricultural Production-Crops Peers: ARVINAS, INC. Axsome Therapeutics, Inc. Pacira BioSciences, Inc. CASSAVA SCIENCES INC Harmony Biosciences Holdings, Inc. JOHNSON & JOHNSON Revance Therapeutics, Inc. Prestige Consumer Healthcare Inc. Ventyx Biosciences, Inc.